281 related articles for article (PubMed ID: 21031435)
1. Differential expression of peroxiredoxins in prostate cancer: consistent upregulation of PRDX3 and PRDX4.
Basu A; Banerjee H; Rojas H; Martinez SR; Roy S; Jia Z; Lilly MB; De León M; Casiano CA
Prostate; 2011 May; 71(7):755-65. PubMed ID: 21031435
[TBL] [Abstract][Full Text] [Related]
2. Peroxiredoxins 3 and 4 are overexpressed in prostate cancer tissue and affect the proliferation of prostate cancer cells in vitro.
Ummanni R; Barreto F; Venz S; Scharf C; Barett C; Mannsperger HA; Brase JC; Kuner R; Schlomm T; Sauter G; Sültmann H; Korf U; Bokemeyer C; Walther R; Brümmendorf TH; Balabanov S
J Proteome Res; 2012 Apr; 11(4):2452-66. PubMed ID: 22424448
[TBL] [Abstract][Full Text] [Related]
3. The prognostic values of the peroxiredoxins family in ovarian cancer.
Li S; Hu X; Ye M; Zhu X
Biosci Rep; 2018 Oct; 38(5):. PubMed ID: 30104402
[No Abstract] [Full Text] [Related]
4. Expression analysis of thrombospondin 2 in prostate cancer and benign prostatic hyperplasia.
Matos AR; Coutinho-Camillo CM; Thuler LC; Fonseca FP; Soares FA; Silva EA; Gimba ER
Exp Mol Pathol; 2013 Jun; 94(3):438-44. PubMed ID: 23470460
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-23b downregulates peroxiredoxin III in human prostate cancer.
He HC; Zhu JG; Chen XB; Chen SM; Han ZD; Dai QS; Ling XH; Fu X; Lin ZY; Deng YH; Qin GQ; Cai C; Chen JH; Zhong WD
FEBS Lett; 2012 Jul; 586(16):2451-8. PubMed ID: 22710126
[TBL] [Abstract][Full Text] [Related]
6. Enhanced expression of SOS1 is detected in prostate cancer epithelial cells from African-American men.
Timofeeva OA; Zhang X; Ressom HW; Varghese RS; Kallakury BV; Wang K; Ji Y; Cheema A; Jung M; Brown ML; Rhim JS; Dritschilo A
Int J Oncol; 2009 Oct; 35(4):751-60. PubMed ID: 19724911
[TBL] [Abstract][Full Text] [Related]
7. High placenta-specific 1/low prostate-specific antigen expression pattern in high-grade prostate adenocarcinoma.
Ghods R; Ghahremani MH; Madjd Z; Asgari M; Abolhasani M; Tavasoli S; Mahmoudi AR; Darzi M; Pasalar P; Jeddi-Tehrani M; Zarnani AH
Cancer Immunol Immunother; 2014 Dec; 63(12):1319-27. PubMed ID: 25186610
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Pleomorphic Adenoma Gene-Like 2 Is a Novel Poor Prognostic Marker of Prostate Cancer.
Guo J; Wang M; Wang Z; Liu X
PLoS One; 2016; 11(8):e0158667. PubMed ID: 27537362
[TBL] [Abstract][Full Text] [Related]
9. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
10. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
[TBL] [Abstract][Full Text] [Related]
11. Expression of CDX2 in benign tissue and adenocarcinoma of the prostate.
Herawi M; De Marzo AM; Kristiansen G; Epstein JI
Hum Pathol; 2007 Jan; 38(1):72-8. PubMed ID: 16949907
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of Talin-1 expression associates with advanced pathological features and predicts lymph node metastases and biochemical recurrence of prostate cancer.
Xu N; Chen HJ; Chen SH; Xue XY; Chen H; Zheng QS; Wei Y; Li XD; Huang JB; Cai H; Sun XL
Medicine (Baltimore); 2016 Jul; 95(29):e4326. PubMed ID: 27442684
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
14. Increasing discordant antioxidant protein levels and enzymatic activities contribute to increasing redox imbalance observed during human prostate cancer progression.
Chaiswing L; Zhong W; Oberley TD
Free Radic Biol Med; 2014 Feb; 67():342-52. PubMed ID: 24269899
[TBL] [Abstract][Full Text] [Related]
15. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
16. High circulating estrogens and selective expression of ERβ in prostate tumors of Americans: implications for racial disparity of prostate cancer.
Abd Elmageed ZY; Moroz K; Srivastav SK; Fang Z; Crawford BE; Moparty K; Thomas R; Abdel-Mageed AB
Carcinogenesis; 2013 Sep; 34(9):2017-23. PubMed ID: 23658372
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence.
Lin B; Utleg AG; Gravdal K; White JT; Halvorsen OJ; Lu W; True LD; Vessella R; Lange PH; Nelson PS; Hood L; Kalland KH; Akslen LA
Clin Cancer Res; 2008 Mar; 14(5):1397-406. PubMed ID: 18316561
[TBL] [Abstract][Full Text] [Related]
19. Low-Molecular-Weight Protein Tyrosine Phosphatase Predicts Prostate Cancer Outcome by Increasing the Metastatic Potential.
Ruela-de-Sousa RR; Hoekstra E; Hoogland AM; Souza Queiroz KC; Peppelenbosch MP; Stubbs AP; Pelizzaro-Rocha K; van Leenders GJLH; Jenster G; Aoyama H; Ferreira CV; Fuhler GM
Eur Urol; 2016 Apr; 69(4):710-719. PubMed ID: 26159288
[TBL] [Abstract][Full Text] [Related]
20. Expression patterns of candidate susceptibility genes HNF1β and CtBP2 in prostate cancer: association with tumor progression.
Debiais-Delpech C; Godet J; Pedretti N; Bernard FX; Irani J; Cathelineau X; Cussenot O; Fromont G
Urol Oncol; 2014 May; 32(4):426-32. PubMed ID: 24332637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
